

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

2. (Previously Amended) A composition having matrix metalloprotease inhibitory activity, comprising a compound of claim 8 and a pharmaceutically acceptable carrier.
3. (Previously Amended) A method of inhibiting matrix metalloprotease activity in a mammal comprising administration of an effective amount matrix metalloprotease inhibitor compound of claim 8 to said mammal.
4. (Original) The method of claim 3 wherein said mammal is a human.
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Previously Added) A matrix metalloproteinase inhibitor selected from the group consisting of:
(rac)-4-(4'-chloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)ethyl]butyric acid; (-)-4-(4'-chloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)ethyl]butyric acid; (+)-4-(4'-chloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)ethyl]butyric acid; and their pharmaceutically acceptable salts.